Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective

Area of Science:

• Oncology
• Immunology
• Cancer Stem Cell Biology

Background:

• Conventional chemotherapies face limitations in treating solid tumors and metastatic diseases, often encountering chemo-resistance and relapse.
• Cancer stem cells (CSCs) are implicated in treatment failure and disease recurrence, necessitating novel therapeutic strategies.
• Immunotherapy presents a promising avenue for cancer treatment, with growing interest in its potential against CSCs.

Purpose of the Study:

• To review and analyze immunotherapy approaches targeting cancer stem cells (CSCs) in solid tumors.
• To compare the strengths and limitations of various immunotherapy strategies against CSCs.
• To highlight the clinical relevance and future potential of immunotherapy in overcoming CSC-mediated resistance.

Main Methods:

• Systematic review of immunotherapy strategies against CSCs in solid tumors.
• Categorization of adaptive immunotherapy (e.g., dendritic cell vaccination) and MHC-unrestricted effectors (e.g., NK cells, γδ T cells, CIK cells).
• Comparative analysis of findings, strengths, and limitations of discussed immunotherapy models.

Main Results:

• CSCs represent a significant biological and clinical target for cancer immunotherapy.
• Preliminary evidence indicates CSCs are susceptible to various immunotherapy attacks, potentially overcoming chemo-resistance.
• Different immunotherapy modalities, including adaptive and MHC-unrestricted approaches, show potential against CSCs.

Conclusions:

• CSCs are a critical target for novel cancer therapies, particularly immunotherapy.
• Immunotherapy offers a potential strategy to overcome CSC-driven chemo-resistance and improve treatment efficacy.
• Future research should address safety concerns and explore synergistic combinations for effective clinical translation.